Results 51 to 60 of about 1,130 (117)

Atypical chronic myeloid leukemia: From diagnosis to molecular features and therapeutic options

HemaSphere, Volume 9, Issue 12, December 2025.
ABSTRACT Atypical chronic myeloid leukemia (aCML) is a rare form of myelodysplastic (MDS)/myeloproliferative neoplasm (MPN) overlap disorder characterized by neutrophilic leukocytosis with circulating immature myeloid cells (IMC), frequent hepatosplenomegaly, and poor prognosis with high rates of leukemic transformation.
Alessandra Iurlo, Daniele Cattaneo, Umberto Gianelli, Francesco Passamonti   +3 more
wiley   +1 more source

Targeting kinases with precision

Molecular & Cellular Oncology, 2018
Cancer genomics and mechanistic studies have revealed that heterogeneous mutations within a single kinase can result in a variety of activation mechanisms.
Alexandra K. Gardino, Erica K. Evans, Joseph L. Kim, Natasja Brooijmans, Brian L. Hodous, Beni Wolf, Christoph Lengauer   +6 more
doaj   +1 more source

Cabozantinib in PDGFRA D842V-Mutated Advanced Gastrointestinal Stromal Tumor: A Case Report with a Review of Literature

Indian Journal of Medical and Paediatric Oncology
Although conventional tyrosine kinase inhibitor have revolutionized the management of KIT and PDGFRA mutant gastrointestinal stromal tumor (GIST), the subset of patients with PDGFRA D842V mutation lags behind, with poor survival outcomes.
Archana Sasi, Sambit Sagar, Shamim Ahmed Shamim, Sameer Rastogi   +3 more
doaj   +1 more source

C018 | OVERALL SURVIVAL AND DURATION OF TREATMENT IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR BEST AVAILABLE THERAPY IN A REAL-WORLD SETTING

Haematologica
Introduction In this retrospective study of the efficacy of avapritinib, a selective KIT D816V inhibitor, in adults with advanced systemic mastocytosis (AdvSM), we compared overall survival (OS) and duration of treatment (DOT) in patients treated with ...
A. M. Vannucchi, A. Reiter, J. Gotlib, I. Álvarez-Twose, D. H. Radia, J. Luebke, P. J. Bobbili, A. Wang, S. Dimitrijević, E. Sullivan, J. Schwaab, I. A. Galinsky, C. Perkins, W. R. Sperr, P. Sriskandarajah, M. Mohan, T. Badu, M. S. Duh, P. Valent   +18 more
doaj  

Progression in treatment of advanced gastrointestinal stromal tumors [PDF]

Waike lilun yu shijian
Gain-of-function mutations in KIT or PDGFRA receptor tyrosine kinase are key drivers of most gastrointestinal stromal tumor (GIST). The continuous development of tyrosine kinase inhibitors, such as imatinib, sunitinib, anlotinib, regorafenib, ripretinib ...
TANG Haixiao, ZHANG Yun, HAN Gang, GONG Hangjun
doaj   +1 more source

First Description of the Clinical Activity of Avapritinib in Sporadic Mesenteric Desmoid Tumor

Case Reports in Oncological Medicine
Desmoid tumors (DTs) are rare and locally aggressive with a high rate of local recurrence even with optimal surgical resection. Systemic treatments are often utilized for desmoid cases with high risk of surgical morbidity or for local and symptomatic ...
Rebecca Ganzon, Wei Chen, Gabriel Tinoco
doaj   +1 more source

Plenary Abstracts Session & Oral Presentations

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

P225 | IMPROVED OUTCOME WITH AVAPRITINIB VS MIDOSTAURIN IN SYSTEMIC MASYOCYTOSIS: A SINGLE-CENTER EXPERIENCE

Haematologica
BACKGROUND: Adverse systemic mastocytosis (AdvSM) includes the most aggressive SM subtypes; cKITD816V is recognized as a driver mutation in ~95% of cases. Therefore, Tyrosine Kinase Inhibitors (TKIs) represent the standard of care. Avapritinib is a new,
M. Fazio, S. Stella, T. Chiara, B. Esposito, A. Duminuco, F. Di Raimondo, A. Romano   +6 more
doaj  

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source